1985
Treatment of diffuse large cell non-Hodgkin’s lymphomas
Fisher R, Devita V, Longo D, Ihde D, Young R. Treatment of diffuse large cell non-Hodgkin’s lymphomas. Developments In Oncology 1985, 465-469. DOI: 10.1007/978-1-4613-2607-6_49.Peer-Reviewed Original ResearchLong-term disease-free survivalDisease-free survivalAdvanced stageAdvanced diffuse histiocytic lymphomaDiffuse mixed lymphomaDiffuse histiocytic lymphomaDiffuse large cellDiffuse aggressive lymphomasLarge cell lymphomaComplete remissionComplete respondersCombination chemotherapyMixed lymphomaAggressive lymphomaHodgkin's lymphomaHistiocytic lymphomaTherapeutic resultsCell lymphomaBurkitt's lymphomaLymphomaFatal diseaseTreatment programPatientsSurvivalLarge cells
1980
The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
Garvin A, Simon R, Young R, DeVita V, Berard C. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications. Seminars In Oncology 1980, 7: 234-43. PMID: 6998002.Peer-Reviewed Original ResearchConceptsLukes-Collins systemNon-Hodgkin's lymphomaLukes-CollinsClassification of non-Hodgkin's lymphomasClinical management of patientsAggressive combination chemotherapyDiffuse histiocytic lymphomaHomogeneous group of patientsManagement of patientsGroup of patientsB symptomsLymphocytic lymphomaCentroblastic-centrocyticCombination chemotherapyDiffuse lymphomaLymphoblastic lymphomaPlasmacytoid differentiationKiel classificationRappaport classificationNodular lymphomaHistiocytic lymphomaRetrospective reviewFollicular patternClinicopathologic entityYounger patientsNodular Histiocytic Lymphoma: An Aggressive Nodular Lymphoma With Potential for Prolonged Disease-Free Survival
Osborne C, Norton L, Young R, Garvin A, Simon R, Berard C, Hubbard S, DeVita V. Nodular Histiocytic Lymphoma: An Aggressive Nodular Lymphoma With Potential for Prolonged Disease-Free Survival. Blood 1980, 56: 98-103. DOI: 10.1182/blood.v56.1.98.98.Peer-Reviewed Original ResearchNodular histiocytic lymphomasDiffuse histiocytic lymphomaHistiocytic lymphomaNodular lymphomaPathological stageProlonged disease-free survivalNatural historyDisease-free survivalLymph node biopsyNon-Hodgkin's lymphomaSubtypes of lymphomaTreated with cyclophosphamideLymph node examinationLymph node histologyGroup of patientsLong-term survivorsNode biopsyCombination chemotherapyNode examinationLiver involvementNode histologyLymphomaTherapeutic strategiesPatientsLymphNodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival.
Osborne C, Norton L, Young R, Garvin A, Simon R, Berard C, Hubbard S, DeVita V. Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. Blood 1980, 56: 98-103. PMID: 6992889, DOI: 10.1182/blood.v56.1.98.bloodjournal56198.Peer-Reviewed Original ResearchConceptsNodular histiocytic lymphomasDiffuse histiocytic lymphomaHistiocytic lymphomaNodular lymphomaPathological stageProlonged disease-free survivalNatural historyLymph node biopsyNon-Hodgkin's lymphomaDisease-free survivalSubtypes of lymphomaTreated with cyclophosphamideLymph node examinationLymph node histologyGroup of patientsLong-term survivorsCombination chemotherapyNode biopsyNode examinationLiver involvementNode histologyLymphomaTherapeutic strategiesPatientsLymphPersistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original Research
1978
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma
Strauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.Peer-Reviewed Original ResearchConceptsComplete response rateDiffuse histiocytic lymphomaHistopathological subclassificationExcellent prognosisIntermediate prognosisBetter prognosisPoor prognosisHistiocytic lymphomaMorphologic subclassificationHistopathological categoriesHeterogeneous diseaseClinical relevancePrognosisResponse rateMorphologic featuresLymphomaChemotherapyPatientsTumorsSubclassificationSurvivalDifferencesDiseaseDiffuse histiocytic lymphoma involving the gastrointestinal tract
Hande K, Fisher R, Devita V, Chabner B, Young R. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer 1978, 41: 1984-1989. PMID: 348299, DOI: 10.1002/1097-0142(197805)41:5<1984::aid-cncr2820410544>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaBowel perforationComplete remissionSurgical resectionHistiocytic lymphomaGastrointestinal tractActive chemotherapeutic regimensMassive intestinal hemorrhageMajority of patientsResults of stagingRigorous stagingGastrointestinal lymphomaSystemic chemotherapySystemic therapyBowel lesionsChemotherapeutic regimensIntestinal hemorrhageDrug therapyRadiation therapyPatientsTumor resistanceLymphomaTherapyRelative rarityWidespread disease
1977
Sequential staging in non-Hodgkin's lymphoma.
Chabner B, Johnson R, DeVita V, Canellos G, Hubbard S, Johnson S, Young R. Sequential staging in non-Hodgkin's lymphoma. Journal Of The National Cancer Institute 1977, 61: 993-7. PMID: 902262.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaInvolvement of bone marrowBone marrow biopsyDiffuse lymphocytic lymphomaType of lymphomaPortal lymph nodesNon-surgical phaseCompletion of stagingNegative lymphangiogramLymphocytic lymphomaMarrow biopsyPositive lymphangiogramHistiocytic lymphomaAbdominal nodesLiver biopsyLymph nodesBone marrowLymphomaPhase of stagingNodular typeStage IIIStage IPatientsResults of stagingLaparotomyPrognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original Research
1976
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.Peer-Reviewed Original ResearchConceptsHistiocytic lymphomaAdvanced diffuse histiocytic lymphomaExtended disease-free survivalMixed histiocytic-lymphocytic lymphomaNew combination chemotherapy programHistiocytic-lymphocytic lymphomaPrednisone combination chemotherapyCompletion of therapyDiscontinuation of treatmentCombination chemotherapy programsDisease-free survivalDiffuse histiocytic lymphomaBone marrow functionMyelosuppressive phaseComplete remissionMedian durationChemotherapy programCombination chemotherapyComplete responseMarrow functionTumor recurrenceTreatment cyclesFatal diseasePatientsLymphomaSequential nonsurgical and surgical staging of non-Hodgkin's lymphoma.
Chabner B, Johnson R, Young R, Canellos G, Hubbard S, Johnson S, DeVita V. Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Annals Of Internal Medicine 1976, 85: 149-54. PMID: 782309, DOI: 10.7326/0003-4819-85-2-149.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaStaging of non-Hodgkin's lymphomaStaging laparotomyLiver biopsyStage III or stage IV diseasePresence of disseminated diseaseDiagnostic proceduresStage IV diseaseBone marrow biopsyPercutaneous liver biopsySequence of diagnostic proceduresNegative lymphangiogramIV diseaseSurgical stagingDisseminated diseaseConsecutive patientsLocalized diseaseNodular lymphomaPositive lymphangiogramHistiocytic lymphomaStaging procedureLymphomaStage IPatientsNonsurgical procedures
1975
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvivalNon‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy
Schein P, Chabner B, Canellos G, Young R, Devita V. Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy. Cancer 1975, 35: 354-357. PMID: 1089470, DOI: 10.1002/1097-0142(197502)35:2<354::aid-cncr2820350209>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsDiffuse histiocytic lymphomaComplete remissionLymphocytic lymphomaCombination chemotherapyHistiocytic lymphomaExtended disease-free survivalDisease-free survivalPatterns of relapseMonths of treatmentMaintenance chemotherapyRemission inductionLymph nodesLate recurrenceHistologic subgroupsHodgkin's lymphomaRemissionBone marrowLymphomaChemotherapyAggressive attemptsPatientsRelapseInitial siteTreatmentRecurrenceADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY
Devita V, Canellos G, Chabner B, Schein P, Hubbard S, Young R. ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY. The Lancet 1975, 305: 248-250. PMID: 46388, DOI: 10.1016/s0140-6736(75)91142-3.Peer-Reviewed Original ResearchConceptsAdvanced diffuse histiocytic lymphomaDiffuse histiocytic lymphomaCombination chemotherapyHistiocytic lymphomaPatients treated with radiotherapyTreated with combination chemotherapySurvival free of diseaseEvidence of tumorFree of diseaseRecurrence of tumorReticulum-cell sarcomaDefinition of cureModern drug treatmentComplete remissionPartial respondersNon-respondersDrug treatmentPatientsSurvival dataLymphomaRemissionChemotherapyNitrogen mustardTumorTreatment